RxDoctor Payments Data

Glenn McClaugherty, MD

Psychiatry · Front Royal, VANPI 1619995669

Payments from drug & device makers

$2,929in general payments, 2019–2025

Across 140 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$734
  • Teva Pharmaceuticals USA, Inc.$473
  • Alkermes, Inc.$357
  • Neurocrine Biosciences, Inc.$315
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$281
  • Otsuka America Pharmaceutical, Inc.$221
  • plus $548 from 10 others

What the payments were for

  • Food & beverage$2,78395%
  • Education$1465%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,929 in reported general payments places this provider in the 85th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$27,306
Medicare patients
80
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate56$170,330
AustedoDeutetrabenazine16$154,332
Austedo XrDeutetrabenazine13$98,252
CaplytaLumateperone Tosylate14$23,198
Clozapine169$11,725
Aripiprazole94$9,748
Lurasidone Hcl30$7,566
Oxcarbazepine190$7,201
Divalproex Sodium ErDivalproex Sodium95$5,600
Divalproex Sodium67$4,803
SavellaMilnacipran Hcl11$4,055
Bupropion XlBupropion Hcl121$3,463
Quetiapine Fumarate200$3,409
Chlorpromazine Hcl14$2,947
Trazodone Hcl267$2,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$473$252,58429 claims
Johnson & JohnsonInvega Sustenna$734$170,33056 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$281$23,19814 claims
AbbVieSavella$133$4,05511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Front Royal

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →